In the BioHarmony Drug Report Database

"Preview" Icon

Satralizumab

Enspryng (satralizumab) is an antibody pharmaceutical. Satralizumab was first approved as Enspryng on 2020-08-14. It is used to treat neuromyelitis optica in the USA. It has been approved in Europe to treat neuromyelitis optica.

 

Trade Name

 

Enspryng
 

Common Name

 

satralizumab
 

ChEMBL ID

 

CHEMBL3833307
 

Indication

 

neuromyelitis optica
 

Drug Class

 

Monoclonal antibodies: humanized, immunomodulating

Image (chem structure or protein)

Satralizumab structure rendering